Compare Mesoblast Limited (MESO) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs SkyWest Inc — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while SkyWest Inc trades at $98.05 (market cap $3.94B). The key difference: SkyWest Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| MESO | SKYW | |
|---|---|---|
Market Cap | $2.17B | $3.94B |
Sector | Technology | Technology |
52-Week High | $20.96 | $123.72 |
52-Week Low | $12.88 | $78.40 |
Enterprise Value | $2.17B | $5.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
SkyWest (SKYW) trades at $99.34, up 2.17% today, with a neutral technical signal but bullish moving averages. The stock shows strong profitability with a 10.42% net margin and attractive valuation at a P/E of 9.32. Recent earnings have been mixed, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results pending. Analyst consensus is bullish with a $109.33 price target, though news highlights concerns over rising fuel costs impacting airline profits.
The outlook for SKYW is cautiously optimistic, supported by solid fundamentals and analyst buy ratings, but faces headwinds from volatile fuel expenses and competitive pressures. Upside potential exists if the company maintains earnings momentum and manages cost inflation, while downside risks include economic sensitivity and operational challenges in the airline industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
